Compare BioNTech SE - ADR (BNTX) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Enbridge Inc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Enbridge Inc trades at $55.87 (market cap $121.05B). The key difference: Enbridge Inc is far larger — about 5.3× BioNTech SE - ADR's market cap, and Enbridge Inc pays a 5.03% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | ENB | |
|---|---|---|
Market Cap | $22.86B | $121.05B |
Sector | Health | Energy |
52-Week High | $119.34 | $58.04 |
52-Week Low | $83.89 | $44.59 |
Enterprise Value | $6.53B | $201.85B |
Dividend Yield | — | 5.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Enbridge (ENB) trades at $55.07, up 0.75% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $65.19 billion in 2025, with net income of $7.49 billion, though it missed Q3 2025 EPS estimates. Analyst sentiment is balanced with a 48% buy rating, and the stock offers a dividend yield supported by over $28 billion in growth projects. Recent news highlights its role in energy infrastructure and AI-driven power demand.
Outlook is cautiously optimistic due to solid cash flow and dividend sustainability, but risks include high debt levels and sensitivity to energy markets. The stock presents a value opportunity for income-focused investors, with earnings on July 31, 2026, as a key near-term catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
